Childhood-onset craniopharyngioma: latest insights into pathology, diagnostics, treatment, and follow-up

References

• Muller HL, Merchant TE, Puget S, et al. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. 2017;13:299–312.
   PubMed Web of Science ®Google Scholar
• Muller HL. Craniopharyngioma. Endocr Rev. 2014;35:513–543.
   PubMed Web of Science ®Google Scholar
• Borrill R, Cheesman E, Stivaros S, et al. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Child Nerv Syst. 2018. doi:10.1007/s00381-018-3925-4. Epub ahead of print.
   Google Scholar
• Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46:161–165.
   PubMed Web of Science ®Google Scholar
• Olsson DS, Andersson E, Bryngelsson IL, et al. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab. 2015;100:467–474.
   PubMed Web of Science ®Google Scholar
• Erfurth EM, Holmer H, Fjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary. 2013;16:46–55.
   PubMed Web of Science ®Google Scholar
• Sterkenburg AS, Hoffmann A, Gebhardt U, et al. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 2015;17:1029–1038.
   PubMed Web of Science ®Google Scholar
• Amelot A, Borha A, Calmon R, et al. Child dermoid cyst mimicking a craniopharyngioma: the benefit of MRI T2-weighted diffusion sequence. Child Nerv Syst. 2018;34:359–362.
   PubMed Web of Science ®Google Scholar
• Terashima KH, Reich DS. Gadolinium deposition: practical guidelines in the face of uncertainty. Lancet Neurol. 2017;16:495–497.
   PubMed Web of Science ®Google Scholar
• de Vile CJ, Grant DB, Hayward RD, et al. Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab. 1996;81:2734–2737.
   PubMed Web of Science ®Google Scholar
• Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab. 2013;98:2376–2382.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Faldum A, et al. Xanthogranuloma, Rathke’s cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations. J Clin Endocrinol Metab. 2012;97:3935–3943.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Teske C, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165:17–24.
   PubMed Web of Science ®Google Scholar
• Fjalldal S, Holmer H, Rylander L, et al. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab. 2013;98:3253–3262.
   PubMed Web of Science ®Google Scholar
• Van Gompel JJ, Nippoldt TB, Higgins DM, et al. Magnetic resonance imaging-graded hypothalamic compression in surgically treated adult craniopharyngiomas determining postoperative obesity. Neurosurg Focus. 2010;28:E3.
   PubMed Web of Science ®Google Scholar
• Elliott RE, Sands SA, Strom RG, et al. Craniopharyngioma clinical status scale: a standardized metric of preoperative function and posttreatment outcome. Neurosurg Focus. 2010;28:E2.
   PubMed Web of Science ®Google Scholar
• Steno J, Bizik I, Steno A, et al. Craniopharyngiomas in children: how radical should the surgeon be?. Child Nerv Syst. 2011;27:41–54.
   PubMed Web of Science ®Google Scholar
• Mallucci C, Pizer B, Blair J, et al. Management of craniopharyngioma: the Liverpool experience following the introduction of the CCLG guidelines. Introducing New Risk Assessment Grading System Child Nerv Syst. 2012;28:1181–1192.
   PubMed Web of Science ®Google Scholar
• Roth CL, Eslamy H, Werny D, et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity (Silver Spring). 2015;23:1226–1233.
   PubMed Web of Science ®Google Scholar
• Mortini P, Gagliardi F, Bailo M, et al. Magnetic resonance imaging as predictor of functional outcome in craniopharyngiomas. Endocrine. 2016;51:148–162.
   PubMed Web of Science ®Google Scholar
• Garre ML, Cama A. Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr. 2007;19:471–479.
   PubMed Web of Science ®Google Scholar
• Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007;106:3–12.
   PubMed Web of Science ®Google Scholar
• Roth CL. Hypothalamic obesity in craniopharyngioma patients: disturbed energy homeostasis related to extent of hypothalamic damage and its implication for obesity intervention. J Clin Med. 2015;4:1774–1797.
   PubMed Web of Science ®Google Scholar
• Muller HL. Preoperative staging in childhood craniopharyngioma: standardization as a first step towards improved outcome. Endocrine. 2016;51:1–3.
   PubMed Web of Science ®Google Scholar
• Martinez-Barbera JP. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma. Neuropath Appl Neurobiol. 2015;41:721–732.
   PubMed Web of Science ®Google Scholar
• Goschzik T, Gessi M, Dreschmann V, et al. Genomic alterations of adamantinomatous and papillary craniopharyngioma. J Neuropathol Exp Neuro. 2017;76:126–134.
   PubMed Web of Science ®Google Scholar
• Stache C, Holsken A, Schlaffer SM, et al. Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol. 2015;25:1–10.
   PubMed Web of Science ®Google Scholar
• Apps JR, Carreno G, Gonzalez-Meljem JM, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135:757–777.
   PubMed Web of Science ®Google Scholar
• Coury JR, Davis BN, Koumas CP, et al. Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review. Neurosurg Rev. 2018 Apr 17. Epub ahead of print. doi:10.1007/s10143-018-0978-5.
   PubMedGoogle Scholar
• Boult JKR, Apps JR, Holsken A, et al. Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. Brain Pathol. 2018;28:475–483.
   PubMed Web of Science ®Google Scholar
• Donson AM, Apps J, Griesinger AM, et al. Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol. 2017;76:779–788.
   PubMed Web of Science ®Google Scholar
• Coy S, Rashid R, Lin JR, et al. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018;20:1101–1112.
   PubMedGoogle Scholar
• Brastianos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016;108:djv310.
   PubMedGoogle Scholar
• Haston S, Pozzi S, Carreno G, et al. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development. 2017;144:2141–2152.
   PubMed Web of Science ®Google Scholar
• Larkin SJ, Preda V, Karavitaki N, et al. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol. 2014;127:927–929.
   PubMed Web of Science ®Google Scholar
• Martinez-Gutierrez JC, D’Andrea MR, Cahill DP, et al. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurg Focus. 2016;41:E2.
   PubMed Web of Science ®Google Scholar
• Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol. 2017;6:95–99.
   PubMedGoogle Scholar
• Rostami E, Witt Nystrom P, Libard S, et al. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir. 2017;159:2217–2221.
   PubMed Web of Science ®Google Scholar
• Himes BT, Ruff MW, Van Gompel JJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. 2018 Apr 27:1–5. doi: 10.3171/2017.11.JNS172373. [Epub ahead of print].
   Google Scholar
• Schlaffer SM, Buchfelder M, Stoehr R, et al. Rathke’s cleft cyst as origin of a pediatric papillary craniopharyngioma. Front Genet. 2018;9:49.
   PubMed Web of Science ®Google Scholar
• Flitsch J, Muller HL, Burkhardt T. Surgical strategies in childhood craniopharyngioma. Front Endocrinol (Lausanne). 2011;2:96.
   PubMedGoogle Scholar
• Buchfelder M, Schlaffer SM, Lin F, et al. Surgery for craniopharyngioma. Pituitary. 2013;16:18–25.
   PubMed Web of Science ®Google Scholar
• Muller HL. Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab. 2011;96:1981–1991.
   PubMed Web of Science ®Google Scholar
• Muller HL. Childhood craniopharyngioma–current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6:609–618.
   PubMed Web of Science ®Google Scholar
• Muller HL. More or less? Treatment strategies in childhood craniopharyngioma. Child Nerv Syst. 2006;22:156–157.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Pohl F, et al. Relapse pattern after complete resection and early progression after incomplete resection of childhood craniopharyngioma. Klin Padiatr. 2006;218:315–320.
   PubMed Web of Science ®Google Scholar
• Kordes U, Flitsch J, Hagel C, et al. Ectopic craniopharyngioma. Klin Padiatr. 2011;223:176–177.
   PubMed Web of Science ®Google Scholar
• Puget S, Grill J, Habrand JL, et al. Multimodal treatment of craniopharyngioma: defining a risk-adapted strategy. J Pediatr Endocrinol Metab. 2006;19:367–370.
   PubMed Web of Science ®Google Scholar
• Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol. 2005;62:397–409.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude children’s research hospital experience 1984-2001. Int J Rad Oncol Biol Phys. 2002;53:533–542.
   PubMed Web of Science ®Google Scholar
• Jane JA Jr., Kiehna E, Payne SC, et al. Early outcomes of endoscopic transsphenoidal surgery for adult craniopharyngiomas. Neurosurg Focus. 2010;28:E9.
   PubMed Web of Science ®Google Scholar
• Cavalheiro S, Sparapani FV, Franco JO, et al. Use of bleomycin in intratumoral chemotherapy for cystic craniopharyngioma. Case Report. J Neurosurg. 1996;84:124–126.
   PubMed Web of Science ®Google Scholar
• Kim SD, Park JY, Park J, et al. Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma. Clin Neurol Neurosurg. 2007;109:236–241.
   PubMed Web of Science ®Google Scholar
• Lafay-Cousin L, Bartels U, Raybaud C, et al. Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report Three Cases J Neurosurg. 2007;107:318–323.
   PubMed Web of Science ®Google Scholar
• Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Child Nerv Syst. 2005;21:719–724.
   PubMed Web of Science ®Google Scholar
• Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus. 2010;28:E12.
   PubMed Web of Science ®Google Scholar
• Bartels U, Laperriere N, Bouffet E, et al. Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne). 2012;3:39.
   PubMedGoogle Scholar
• Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol. 2017;19:1398–1407.
   PubMed Web of Science ®Google Scholar
• Fitzek MM, Linggood RM, Adams J, et al. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Rad Oncol Biol Phys. 2006;64:1348–1354.
   PubMed Web of Science ®Google Scholar
• Luu QT, Loredo LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J. 2006;12:155–159.
   PubMed Web of Science ®Google Scholar
• Winkfield KM, Linsenmeier C, Yock TI, et al. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int J Rad Oncol Biol Phys. 2009;73:716–721.
   PubMed Web of Science ®Google Scholar
• Ajithkumar T, Mazhari AL, Stickan-Verfurth M, et al. Proton therapy for craniopharyngioma - an early report from a single european centre. Clin Oncol (R Coll Radiol). 2018;30:307–316.
   PubMed Web of Science ®Google Scholar
• Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Rad Oncol Biol Phys. 2012;82:643–652.
   PubMed Web of Science ®Google Scholar
• Caldarelli M, Massimi L, Tamburrini G, et al. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Child Nerv Syst. 2005;21:747–757.
   PubMed Web of Science ®Google Scholar
• Muller HL. Childhood craniopharyngioma. Recent Advances Diagnosis, Treatment Follow-Up Horm Res. 2008;69:193–202.
   Google Scholar
• Elliott RE, Wisoff JH. Surgical management of giant pediatric craniopharyngiomas. J Neurosurg Pediatr. 2010;6:403–416.
   PubMed Web of Science ®Google Scholar
• Muller HL, Emser A, Faldum A, et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89:3298–3305.
   PubMed Web of Science ®Google Scholar
• Poretti A, Grotzer MA, Ribi K, et al. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46:220–229.
   PubMed Web of Science ®Google Scholar
• Elliott RE, Jane JA Jr, Wisoff JH. Surgical management of craniopharyngiomas in children: meta-analysis and comparison of transcranial and transsphenoidal approaches. Neurosurgery. 2011;69: 630–643. discussion 643.
   PubMed Web of Science ®Google Scholar
• Müller HL, Schneider P, Bueb K, et al. Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes. 2003;111:168–173.
   PubMed Web of Science ®Google Scholar
• Mortini P, Losa M, Pozzobon G, et al. Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg. 2011;114:1350–1359.
   PubMed Web of Science ®Google Scholar
• Kendall-Taylor P, Jonsson PJ, Abs R, et al. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol. 2005;152:557–567.
   PubMed Web of Science ®Google Scholar
• Ahmet A, Blaser S, Stephens D, et al. Weight gain in craniopharyngioma–a model for hypothalamic obesity. J Pediatr Endocrinol Metab. 2006;19:121–127.
   PubMed Web of Science ®Google Scholar
• Halac I, Zimmerman D. Endocrine manifestations of craniopharyngioma. Child Nerv Syst. 2005;21:640–648.
   PubMed Web of Science ®Google Scholar
• Crom D, Smith D, Xiong Z, et al. Health status in long-term survivors of pediatric craniopharyngiomas. J Neurosci Nurs. 2010;42:323–328.
   PubMed Web of Science ®Google Scholar
• Geffner M, Lundberg M, Koltowska-Haggstrom M, et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (pfizer international growth database). J Clin Endocrinol Metab. 2004;89:5435–5440.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Ogle GD, Garnett SP, et al. Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89:81–86.
   PubMed Web of Science ®Google Scholar
• Muller HL, Bueb K, Bartels U, et al. Obesity after childhood craniopharyngioma–german multicenter study on pre-operative risk factors and quality of life. Klin Padiatr. 2001;213:244–249.
   PubMed Web of Science ®Google Scholar
• Heinks K, Boekhoff S, Hoffmann A, et al. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine. 2018;59:364–372.
   PubMed Web of Science ®Google Scholar
• Elliott RE, Jane JA Jr., Wisoff JH. Surgical management of craniopharyngiomas in children: meta-analysis and comparison of transcranial and transsphenoidal approaches. Neurosurgery. 2011;69:630–643.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Warmuth-Metz M, Lohle K, et al. Fusiform dilatation of the internal carotid artery in childhood-onset craniopharyngioma: multicenter study on incidence and long-term outcome. Pituitary. 2016;19:422–428.
   PubMed Web of Science ®Google Scholar
• Van Effenterre R, Boch AL. Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg. 2002;97:3–11.
   PubMed Web of Science ®Google Scholar
• Muller HL, Faldum A, Etavard-Gorris N, et al. Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma. Klin Padiatr. 2003;215:310–314.
   PubMed Web of Science ®Google Scholar
• Muller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Child Nerv Syst. 2005;21:975–980.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Faldum A, et al. Functional capacity and body mass index in patients with sellar masses–cross-sectional study on 403 patients diagnosed during childhood and adolescence. Child Nerv Syst. 2005;21:539–545.
   PubMed Web of Science ®Google Scholar
• Ondruch A, Maryniak A, Kropiwnicki T, et al. Cognitive and social functioning in children and adolescents after the removal of craniopharyngioma. Child Nerv Syst. 2011;27:391–397.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Schroder S, et al. Analyses of treatment variables for patients with childhood craniopharyngioma–results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up. Horm Res Paediatr. 2010;73:175–180.
   PubMed Web of Science ®Google Scholar
• Kiehna E, Mulhern R, Li C, et al. Changes in attentional performance of children and young adults iwth localized primary brain tumors after conformal radiation therapy. J Clin Oncol. 2006;24:5283–5290.
   PubMed Web of Science ®Google Scholar
• Carpentieri S, Waber D, Scott R, et al. Memory deficits among children with craniopharyngioma. Neurosurgery. 2001;49:1053–1058.
   PubMed Web of Science ®Google Scholar
• Sands S, Milner J, Goldberg J, et al. Quality of life and behavioral follow-up study of pediatric survivors of cranipharyngioma. J Neurosurg (Pediatr). 2005;103:302–311.
   PubMed Web of Science ®Google Scholar
• Ozyurt J, Muller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol. 2015;125:9–21.
   PubMed Web of Science ®Google Scholar
• Ozyurt J, Thiel CM, Lorenzen A, et al. Neuropsychological outcome in patients with childhood craniopharyngioma and hypothalamic involvement. J Pediatr. 2014;164(876–81):e874.
   Google Scholar
• Mehren A, Ozyurt J, Zu Klampen P, et al. Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. J Neurooncol. 2018. Epub ahead of print. DOI:10.1007/s11060-018-2936-z.
   PubMedGoogle Scholar
• Hammond J, Hall S. Functional analysis and treatment of aggressive behavior following resection of a craniopharyngioma. Dev Med Child Neurol. 2011;53:369–374.
   PubMed Web of Science ®Google Scholar
• Cohen M, Guger S, Hamilton J. Long term sequelae of pediatric craniopharyngioma - literature review and 20 years of experience. Front Endocrinol (Lausanne). 2011;2:81.
   PubMedGoogle Scholar
• Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156:887–892.
   PubMedGoogle Scholar
• Ismail D, O’Connell MA, Zacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab. 2006;19:129–134.
   PubMed Web of Science ®Google Scholar
• Elfers CT, Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front Endocrinol (Lausanne). 2011;2:78.
   PubMedGoogle Scholar
• Lustig RH. Hypothalamic obesity: causes, consequences, treatment. Pediatr Endocrinol Rev. 2008;6:220–227.
   PubMedGoogle Scholar
• Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586–2592.
   PubMed Web of Science ®Google Scholar
• Shoemaker A, Proietto J, Abuzzahab MJ, et al. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity. Diabetes Obes Metab. 2017;19:1165–1170.
   PubMed Web of Science ®Google Scholar
• Zoicas F, Droste M, Mayr B, et al. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168:699–706.
   PubMed Web of Science ®Google Scholar
• Daubenbuchel AM, Hoffmann A, Eveslage M, et al. Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine. 2016;54:524–531.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Ozyurt J, Lohle K, et al. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine. 2017;56:175–185.
   PubMed Web of Science ®Google Scholar
• Cook N, Miller J, Hart J. Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. J Pediatr Endocrinol Metab. 2016;29:995–1000.
   PubMed Web of Science ®Google Scholar
• Hsu EA, Miller JL, Perez FA, et al. Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. J Clin Endocrinol Metab. 2018;103:370–375.
   PubMed Web of Science ®Google Scholar
• Meijneke RW, Schouten-van Meeteren AY, de Boer NY, et al. Hypothalamic obesity after treatment for craniopharyngioma: the importance of the home environment. J Pediatr Endocrinol Metab. 2015;28:59–63.
   PubMed Web of Science ®Google Scholar
• Nemergut DR, Townsend AR. The importance of interdisciplinary communication with patients about complex, chronic illnesses: our experiences as parents of a child with a craniopharyngioma. J Pediatr Endocrinol Metab. 2015;28:3–5.
   PubMed Web of Science ®Google Scholar
• Muller HL, Gebhardt U, Wessel V, et al. First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin Padiatr. 2007;219:323–325.
   PubMed Web of Science ®Google Scholar
• Inge TH, Pfluger P, Zeller M, et al. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocrinol Metab. 2007;3:606–609.
   PubMedGoogle Scholar
• Muller HL, Gebhardt U, Maroske J, et al. Long-term follow-up of morbidly obese patients with childhood craniopharyngioma after laparoscopic adjustable gastric banding (LAGB). Klin Padiatr. 2011;223:372–373.
   PubMed Web of Science ®Google Scholar
• Bretault M, Boillot A, Muzard L, et al. Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab. 2013;98:2239–2246.
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Barkan AL, Buchfelder M, et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20:489–498.
   PubMed Web of Science ®Google Scholar